Title: Cardioprotective actions of erythropoietin - are we ready for clinical application?
- Mateusz ?piewak, Krzysztof J. Filipiak
- Review articles
- Polish Journal of Cardiology
- Start page:
- Final page:
- erythropoietin, cardioprotective actions, pleiotropic actions
Erythropoietin (EPO) has a well established role in treating anemia associated with chronić renal failure, in patients receiving chemotherapy, in zidovudine-treated HIV-infected patients. Sińce the discovery of new actions of EPO beyond erythropoiesis, a continuous increase in the number of works concerning cytopro-tective action of EPO has been observed. EPO is known to stimulate angiogenesis, promotes progenitor celi mobilization and proliferation. Basic science research to establish molecular mechanism and experimen-tal research to prove various hypothesis on animal models of nervous system and heart injury are prefor-med. Most of the results are optimistic also in so far the only study on humans. EPO administration in an acute phase of myocardial infarction or stroke might be an innovative way of treatment. However, uncerta-inty remains regarding possibleadresseeffects, in particular- prothrombotic action. Nonerythropoietic de-rivatives of erythropoietin are known. Further studies on their safety and efficiency are warranted.